ATE325876T1 - Isolierte peptide, die an hla-c moleküle binden und deren verwendung - Google Patents

Isolierte peptide, die an hla-c moleküle binden und deren verwendung

Info

Publication number
ATE325876T1
ATE325876T1 AT01973479T AT01973479T ATE325876T1 AT E325876 T1 ATE325876 T1 AT E325876T1 AT 01973479 T AT01973479 T AT 01973479T AT 01973479 T AT01973479 T AT 01973479T AT E325876 T1 ATE325876 T1 AT E325876T1
Authority
AT
Austria
Prior art keywords
hla
molecules
bind
isolated peptides
peptides
Prior art date
Application number
AT01973479T
Other languages
English (en)
Inventor
Sacha Ludwig Gnjatic
Lloyd J Old
Yasuhiro Nagata
Elke Jager
Yao-Tseng Chen
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cornell Res Foundation Inc filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE325876T1 publication Critical patent/ATE325876T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01973479T 2000-09-26 2001-09-24 Isolierte peptide, die an hla-c moleküle binden und deren verwendung ATE325876T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/670,456 US6506875B1 (en) 2000-09-26 2000-09-26 Isolated peptides which bind to HLA-C molecules and uses thereof

Publications (1)

Publication Number Publication Date
ATE325876T1 true ATE325876T1 (de) 2006-06-15

Family

ID=24690468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973479T ATE325876T1 (de) 2000-09-26 2001-09-24 Isolierte peptide, die an hla-c moleküle binden und deren verwendung

Country Status (9)

Country Link
US (2) US6506875B1 (de)
EP (1) EP1320609B1 (de)
JP (1) JP4174570B2 (de)
CN (1) CN1253572C (de)
AT (1) ATE325876T1 (de)
AU (2) AU9305101A (de)
CA (1) CA2423481C (de)
DE (1) DE60119552T2 (de)
WO (1) WO2002026778A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN113795584B (zh) 2019-03-04 2025-09-30 大学健康网络 T细胞受体及其使用方法
KR20210149051A (ko) * 2019-03-04 2021-12-08 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
AU2020245270A1 (en) 2019-03-25 2021-10-14 University Health Network T cell receptors and methods of use thereof
CN120397921B (zh) * 2025-05-28 2025-12-02 江苏新恒鼎装备制造有限公司 一种具有自锁功能的船用曲轴红套升降平台

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
KR20010024877A (ko) * 1998-01-23 2001-03-26 에드워드 에이. 맥더모 2세 분리된, ｈｌａ-ａ29에 결합하는 폴리펩티드, 핵산,이것을 암호화하는 분자, 및 그것의 사용
EP1117679B9 (de) * 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
WO2001062917A1 (en) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof

Also Published As

Publication number Publication date
AU9305101A (en) 2002-04-08
WO2002026778A3 (en) 2003-02-13
JP2004524271A (ja) 2004-08-12
US6506875B1 (en) 2003-01-14
EP1320609B1 (de) 2006-05-10
CN1476480A (zh) 2004-02-18
US20030050451A1 (en) 2003-03-13
DE60119552T2 (de) 2007-04-19
HK1060594A1 (en) 2004-08-13
WO2002026778A2 (en) 2002-04-04
DE60119552D1 (de) 2006-06-14
EP1320609A2 (de) 2003-06-25
CA2423481A1 (en) 2002-04-04
JP4174570B2 (ja) 2008-11-05
CN1253572C (zh) 2006-04-26
CA2423481C (en) 2008-06-10
US7009035B2 (en) 2006-03-07
AU2001293051B2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DK0941478T4 (da) Assaymetode for peptidspecifikke T-celler
DE69636450D1 (de) PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
MY109957A (en) Improved antibodies to plasmodium falciparum
ATE325876T1 (de) Isolierte peptide, die an hla-c moleküle binden und deren verwendung
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
IL123189A0 (en) Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides
EP0739350A4 (de) Fas-antigenbindender ligand
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
ATE362941T1 (de) Identifikation, reinigung und verwendungen von leczymen und karbohydratliganden
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
ATE405582T1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320609

Country of ref document: EP